Eli Lilly Investing Additional $1 Billion in Ireland Manufacturing Plant

By Colin Kellaher

Eli Lilly is spending another $1 billion to expand its manufacturing operations in Ireland amid a burgeoning portfolio of treatments for diabetes, obesity and Alzheimer's disease.

Eli Lilly on Thursday said it will now invest $2 billion in a new manufacturing site in Limerick that will increase production of biologic active ingredients, including those for its recently approved Kisunla treatment for early symptomatic Alzheimer's disease.

The Indianapolis drugmaker, which unveiled plans to spend $500 million on the Limerick plant in 2022 and doubled down on the investment last year, said the additional investment will create another 150 jobs in Limerick, for a total of 450, with production on track to start in 2026.

Eli Lilly on Thursday also officially opened a new $800 million facility expansion in Kinsale, where the company made its first investment in Ireland in 1978.

The new Kinsale operation began making medicines last year to meet surging demand for the company's blockbuster diabetes drug Mounjaro and its related obesity treatment Zepbound.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

September 12, 2024 08:13 ET (12:13 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.